ARCHIVES

An old drug’s 21st century makeover begins with 84-fold price increase. Price hike of procarbazine astonishes brain tumor specialists.

This article is from The Cancer Letter archive.

Vol. 31 No. 19 | May 13, 2005

Download PDF Visit The Full Archive

Related Articles

In Brief: Taxol Development Is NCI ‘Emergency Priority’, Dodd To Focus ACS Effort On Breast Screening

December 7, 1990

Afinitor Delayed Progression Compared To Tamoxifen Alone In Randomized Phase II Study

December 31, 2010

NIH And E.I. Dupont Sign OncoMouse Agreement.

January 28, 2000

Panel Says NIH Must Devise Means For Early Release Of Trials Data

January 25, 1991

Patients on Hypertension Meds Lived Longer, Analysis Shows

January 31, 2014

First shakeup In Upton Regime: Peters Moves Out As DCCP Head To Become “Special Assistant”

September 30, 1977